Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RNAStructuromeDB: a transcriptome-wide database of predicted RNA secondary structures with integrated APIs for functional annotation and RNA-targeted drug discovery. | NAR Genom Bioinform | 2026 | 42078568 | PubTator, text mining | PubMed |
| Combining SMN2 splicing modifiers with HDAC6 inhibition improves spinal muscular atrophy outcomes. | Brain | 2026 | 42068140 | PubTator, text mining | PubMed |
| MyomiR Networks in Spinal Muscular Atrophy: Associations With Clinical Severity and Treatment Response. | Mol Neurobiol | 2026 | 42062642 | PubTator, text mining | PubMed |
Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study. | EClinicalMedicine | 2026 | 42016922 | PubTator, text mining | PubMed |
| Systematic Druggable Genome-Wide Analysis Identifies Therapeutic Targets for Aging: A Mendelian Randomization Study. | Health Sci Rep | 2026 | 42005663 | PubTator, text mining | PubMed |
| [Frequency of 5q spinal muscular atrophy in adults with unspecified neuromuscular diseases]. | Zh Nevrol Psikhiatr Im S S Korsakova | 2026 | 41984556 | PubTator, text mining | PubMed |
| Haloperidol induces neuroprotection and enhances neuromuscular function in both murine and human models of spinal muscular atrophy. | Exp Mol Med | 2026 | 41974892 | PubTator, text mining | PubMed |
| Risdiplam Add-On Therapy Following Onasemnogene Abeparvovec in Children With Spinal Muscular Atrophy and 2 SMN2 Copies: A Multi-Center Case Series. | Muscle Nerve | 2026 | 41964328 | PubTator, text mining | PubMed |
| Locked nucleic acid (LNA) based PCR approach for the diagnosis and screening of spinal muscular atrophy. | Indian J Med Res | 2026 | 41949145 | PubTator, text mining | PubMed |
| Clinical Experience of Timing Treatment in Newborns with Spinal Muscular Atrophy: A Call for Standardized Screening Practices in Italy. | Int J Neonatal Screen | 2026 | 41892024 | PubTator, text mining | PubMed |
| Trends in the Timeliness of Spinal Muscular Atrophy Detection in US Infants, 2016-2023. | Int J Neonatal Screen | 2026 | 41892017 | PubTator, text mining | PubMed |
| Fibro-adipogenic progenitor cells from murine SMA muscles are intrinsically adipogenic. | Proc Natl Acad Sci U S A | 2026 | 41886383 | PubTator, text mining | PubMed |
| Alternative splicing in voltage-gated sodium channels: mechanisms, regulatory networks and therapeutic implications. | Ann Med | 2026 | 41869747 | PubTator, text mining | PubMed |
| Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry. | Ann Clin Transl Neurol | 2026 | 41854353 | PubTator, text mining | PubMed |
| The Dynamics of Neurofilament Light Chain in Spinal Muscular Atrophy. | Ann Neurol | 2026 | 41845532 | PubTator, text mining | PubMed |
| Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI. | J Neuromuscul Dis | 2026 | 41830094 | PubTator, text mining | PubMed |
| Longitudinal multi-omics profiling of spinal muscular atrophy. | Neurotherapeutics | 2026 | 41825231 | PubTator, text mining | PubMed |
| A prospective, multi-center, observational study of the safety, tolerability and effectiveness of Nusinersen in adult patients with spinal muscular atrophy. | Neuromuscul Disord | 2026 | 41813449 | PubTator, text mining | PubMed |
| RNA localization to nuclear speckles follows splicing logic. | Nucleic Acids Res | 2026 | 41787512 | PubTator, text mining | PubMed |
| Workshop report: Findings from the 2025 Italian SMAkers Educational Initiative on SMA management in Italy. | J Neurol Sci | 2026 | 41780423 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=4